In parallel, there is growing focus on small molecule GLP-1R agonists , which have the potential to be administered orally, produced more cost-effectively, and offer improved stability and pharmacokinetic profiles
Interestingly, bile acid metabolites have a dual effect on GLP-1 secretion: they can both stimulate and inhibit its production (66)
This hypothalamus/hindbrain focused model of GLP-1 action, however, does not easily accommodate the recent findings showing that GLP-1R stimulation reduces food reward behavior (Dickson et al., 1984
This process varies from person to person, but many individuals report a noticeable decrease in hunger within the first few weeks of starting GLP-1 medication
48 Patients with HFpEF and obesity are usually younger than HFpEF patients without obesity
3,5 Pfizer also announced the development of danuglipron